Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples